Salih Demir
Overview
Explore the profile of Salih Demir including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
183
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Demir S, Hotes A, Schmid T, Cairo S, Indersie E, Pisano C, et al.
J Exp Clin Cancer Res
. 2024 Nov;
43(1):299.
PMID: 39529166
Background: Patients with metastatic hepatoblastoma are treated with severely toxic first-line chemotherapies in combination with surgery. Yet, inadequate response of lung metastases to neo-adjuvant chemotherapy still compromises patient outcomes making...
2.
Turkmen K, Baloglu I, Aykut T, Demir S, Altin E, Akguzel Z, et al.
Saudi J Kidney Dis Transpl
. 2024 Jul;
34(5):406-415.
PMID: 38995299
Fabry disease (FD) is associated with inflammation, proteinuria, and chronic kidney disease. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) plays an important role in inflammation in diabetic nephropathy and...
3.
Demir S, Razizadeh N, Indersie E, Branchereau S, Cairo S, Kappler R
Hepatol Commun
. 2024 Jan;
8(2).
PMID: 38285887
Background: As the variable clinical outcome of patients with hepatoblastoma (HB) cannot be explained by genetics alone, the identification of drugs with the potential to effectively reverse epigenetic alterations is...
4.
Weigl E, Demir S, Schmid T, Hotes A, Muensterer O, Kappler R
Front Bioeng Biotechnol
. 2023 Dec;
11:1229490.
PMID: 38076431
Emerging technologies such as three-dimensional (3D) cell culture and the generation of biological matrices offer exciting new possibilities in disease modelling and tumour therapy. The paucity of laboratory models for...
5.
Failli M, Demir S, Del Rio-Alvarez A, Carrillo-Reixach J, Royo L, Domingo-Sabat M, et al.
Hepatology
. 2023 Sep;
80(1):55-68.
PMID: 37729391
Background And Aims: Hepatoblastoma (HB) is the predominant form of pediatric liver cancer, though it remains exceptionally rare. While treatment outcomes for children with HB have improved, patients with advanced...
6.
Li Q, Demir S, Del Rio-Alvarez A, Maxwell R, Wagner A, Carrillo-Reixach J, et al.
Cancers (Basel)
. 2022 Sep;
14(17).
PMID: 36077733
Resistance to conventional chemotherapy remains a huge challenge in the clinical management of hepatoblastoma, the most common liver tumor in childhood. By integrating the gene expression data of hepatoblastoma patients...
7.
Koca A, Polat O, Oguz A, Genc S, Gunalp M, Degirmenci S, et al.
Disaster Med Public Health Prep
. 2022 Jun;
17:e162.
PMID: 35765149
Objective: Triage is a tool used to determine patients' severity of illness or injury within minutes of arrival. This study aims to assess the reliability and validity of a new...
8.
Osmanoglu M, Demir S, Tugrul B
PeerJ Comput Sci
. 2022 Jun;
8:e965.
PMID: 35721407
Cloud computing enables users to outsource their databases and the computing functionalities to a cloud service provider to avoid the cost of maintaining a private storage and computational requirements. It...
9.
Goktug A, Cullas Ilarslan N, Vatansever G, Ozdemir I, Polat O, Oguz A, et al.
Pediatr Emerg Care
. 2022 May;
39(1):28-32.
PMID: 35580177
Background: The intensity of emergency services is an increasing health problem all over the world, necessitating an effective triage system. The aim of this study was to evaluate the validity...
10.
Kolorz J, Demir S, Gottschlich A, Beirith I, Ilmer M, Luthy D, et al.
Curr Oncol
. 2022 Jan;
29(1):94-110.
PMID: 35049682
Rhabdoid tumors (RT) are among the most aggressive tumors in early childhood. Overall survival remains poor, and treatment only effectively occurs at the cost of high toxicity and late adverse...